To determine whether luteinising hormone-releasing hormone (LHRH) agonist, ATRIGEL â polymer-delivered, subcutaneous, leuprolide acetate (ADSC-LA), formulations suppressed serum testosterone to concentrations of ≤20 ng/ dL.
Introduction
Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer, alleviating symptoms and extending overall survival. Historically, the goal of chemical ADT was to achieve the same level of testosterone suppression as attained by bilateral orchidectomy. Therefore, achieving a serum testosterone concentration of ≤50 ng/dL during ADT was considered the 'gold standard' target for advanced prostate cancer [1] [2] [3] ; however, this level was notably based on the limit of sensitivity for testosterone assays available at the time. More recently, using assays with improved sensitivities, several studies have shown that bilateral orchidectomy results in consistent serum testosterone concentrations of ≤20 ng/dL. For example, using a chemiluminescent assay in a study of 25 men who underwent bilateral orchidectomy, Oefelein et al. [3] reported a mean testosterone concentration of 15 ng/dL. Similar results (mean serum testosterone concentration of 9.2 ng/dL; 97% <20 ng/ dL) were reported using an isotope dilution-liquid chromatography-tandem mass spectrometry methodology in a study of 34 men after orchidectomy [4] .
Recent studies have shown that lower serum testosterone concentrations during ADT (as low as <20 ng/dL) are associated with improved clinical outcomes in patients with advanced prostate cancer or biochemical failure after local therapy. In a retrospective study of 129 patients with metastatic prostate cancer treated with ADT, higher testosterone concentrations at 6 months increased the risk of death by 1.33-times (P < 0.05) [5] . In a prospective cohort study of 32 patients with metastatic, locally-advanced, or recurrent prostate cancer, those with first year mean testosterone concentrations of <32 ng/dL had increased time to castrate-resistant prostate cancer compared with patients with testosterone values of 32-50 ng/dL (median progression-free survival 33.1 vs 12.5 months; P = 0.05) [6] . In a prospective study of 153 patients with metastatic disease or biochemical failure treated with ADT, a serum testosterone concentration of <20 ng/dL was associated with a lower risk of death (adjusted hazard ratio 0.19; P = 0.02) [7] . Finally, in a secondary analysis of 626 patients with biochemical failure after local therapy from a large prospective trial cohort, those with a higher nadir testosterone (≥20 ng/dL) had a higher risk of dying from prostate cancer and developing castrate resistance [8] .
Complementary evidence comes from a study of maintenance ADT in 73 patients with non-metastatic disease. In that study, patients with breakthrough increases of >32 ng/dL had lower progression-free survival than those with lower testosterone concentrations (88 vs 137 months; P < 0.03) [9] . Thus, avoidance of even small testosterone 'escapes' and 'mini-flares' above castrate concentrations has been recommended [10] .
Given the recent evidence, both the definition of castrate testosterone concentration and clinical practice recommendations for achieving chemical castration have been updated. The European Association of Urology guidelines have reduced their clinical definition of castration to a testosterone concentration of <20 ng/dL [11] and there has been debate amongst clinicians whether clinical standards should be updated to reflect the results of recent studies. However, regulatory authorities in the European Union, as well as the USA, continue to define castrate concentrations for testosterone as <50 ng/dL, which is the historical threshold used in clinical trials for approval of ADT drugs in patients with prostate cancer.
Leuprolide acetate (LA) with ATRIGEL â delivery system (Eligard â ; Tolmar, Inc., Fort Collins, CO, USA; ADSC-LA) is an extended release, subcutaneously (s.c.) administered formulation of LA. The delivery system contains a uniquely formulated, biodegradable polymer of D, L-lactide-coglycolide dissolved in N-methyl-2-pyrrolidone, creating a liquid drug formulation that forms a solid, slow-release implant after coming into contact with s.c. fluid. It was previously reported that during the pharmacokinetic plateau phase (days 7-168), median LA concentrations ranged from 0.1 to 3.0 ng/mL after the first dose of 6-month ADSC-LA. The safety and efficacy of four different formulations of ADSC-LA have been established in clinical trials for regulatory authorities' approval in the USA and elsewhere. However, these trials reported testosterone suppression results using a target of <50 ng/dL [12] [13] [14] [15] . Given the importance of reducing testosterone to concentrations equivalent to those achieved by surgical castration, the objective of this analysis was to evaluate the pivotal trial data for the 1-, 3-, 4-, and 6-month dose formulations of ADSC-LA to determine the efficacy of testosterone suppression to ≤20 ng/dL.
Patients and Methods
This study was an analysis of four prospective, open-label, fixed-dose clinical trials of patients with advanced adenocarcinoma of the prostate and treated with ADSC-LA [12] [13] [14] [15] . The primary analyses were mean serum testosterone concentrations and proportion of patients who achieved serum testosterone concentrations of ≤20 ng/dL.
Individual study designs, procedures, and patient populations have been previously reported. Briefly, in the four clinical trials, male patients aged 40-86 years with prostate cancer, whom had not previously undergone ADT, were treated with one of four s.c. formulations of ADSC-LA (Fig. 1) . The 1-month formulation (120 patients) contained 7.5 mg of LA, administered once every 28 days for 24 weeks (six doses). The 3-month formulation (117 patients) contained 22.5 mg of LA, administered once every 90 days for 24 weeks (two doses). The 4-month formulation (90 patients) contained 30 mg of LA, administered once every 120 days for 32 weeks (two doses). The 6-month formulation (111 patients) contained 45 mg of LA, administered once every 6 months for 48 weeks (two doses). The primary endpoint of all four studies was serum testosterone concentration at the sampling time points. Serum testosterone was sampled at screening, baseline, 2, 4, and 8 h after dosing, days 1, 2, 3, and 7, and every week until the next dose, at which time, the sampling schedule repeated until the end of study. Secondary endpoints included serum luteinising hormone (LH) concentration, measure of bone pain, urinary pain and urinary signs and symptoms, and WHO performance status score.
The study drug, ADSC-LA, was supplied in two separate sterile syringes and mixed within 30 min prior to administration. One syringe contained the ATRIGEL polymer formulation and the other contained lyophilised LA. The contents of the syringes were thoroughly mixed in accordance Descriptive statistics were used to summarise the concentrations at each time point, as well as time to testosterone suppression of ≤20 ng/dL. The proportion of patients reaching the ≤20 ng/dL threshold testosterone concentration was calculated at each time point.
Results

Baseline Characteristics
Baseline characteristics and demographics (Table 1) were representative and similar between study cohorts. All trials enrolled patients with advanced adenocarcinoma of the prostate. The mean serum testosterone concentration was 361-386 ng/dL across study cohorts; the mean PSA concentration varied between 13.2 and 86.4 ng/mL across cohorts.
Primary Efficacy Analysis
The mean (SE) serum testosterone concentrations at the end of each study were <20 ng/dL for each dose: 6.1 (0.4), 10.1 (0.7), 12.4 (0.8), 12.6 (2.1) for the 1-, 3-, 4-, and 6-month formulations, respectively ( Table 2 ). The mean testosterone suppression was consistently maintained at ≤20 ng/dL during weeks 5 to final time point (up to 48 weeks) in all four studies (Fig. 2) . Across all studies and formulations of ADSC-LA, >90% of patients had suppressed mean testosterone concentrations to ≤20 ng/dL by week 6 (Fig. 3) . The mean serum testosterone concentration was maintained at ≤20 ng/dL over 24 weeks with all four dose formulations (Fig. 4) . During the trial of the 6-month formulation, testosterone suppression to ≤20 ng/dL was achieved in 4 weeks (Fig. 4) , and the mean serum testosterone concentration remained below this level for 6 months (Figs 2,4) . In the same 6-month formulation study, between weeks 6 and 24, 92-96% of patients at each measured time point had serum testosterone concentrations of ≤20 ng/dL (Fig. 3) .
Secondary Efficacy Analysis
In all the studies, after injection of ADSC-LA, LH concentrations increased transiently through the first day and were at or below baseline values by day 7. LH concentrations were consistently below 1 IU/L throughout the remainder of each study. PSA values were reduced with all dose formulations: reductions from baseline were 94% with the 1-month formulation (at month 6), 98% with the 3-month formulation (at month 6), 86% with 4-month formulation (at month 8), and 97% with 6-month formulation (at month 12). At the end of each trial, the percentage of patients with PSA concentrations of <4 ng/mL were 96%, 93%, 95%, and 96%, for the 1-, 3-, 4-, and 6-month formulations, respectively. Across studies, WHO performance status remained stable. Measures of bone pain, urinary pain, and urinary signs and symptoms were low at baseline and remained low during the study. There were no increases in scores associated with symptomatic flares in the 3 days after dosing.
Safety
The safety profiles were similar between study cohorts and were as expected for treatment with an LHRH agonist ( Table 3 ). The most common adverse event (AE) was hot flashes and sweats (56-73% across every study), which is an expected pharmacological consequences of testosterone suppression. Pain at the injection site was reported in 2.3-4.6% of injections across studies. One treatment-related serious AE was reported in the 4-month formulation study (hospitalisation for severe depression with suicidal ideation). No cardiovascular serious AE or other treatment-related serious AEs were reported across the four studies.
Discussion
Increasing evidence suggests that the historical target threshold for serum testosterone concentration when using ADT in treating advanced prostate cancer (≤50 ng/dL) is not equivalent to the concentrations achieved by surgical castration [5] [6] [7] [8] [9] . The optimal testosterone target concentration is an ongoing subject of scientific debate; however, clinical practice guidelines have already begun to (10) 16 (14) 1-month dose (n = 120) 60 move towards recommending lower thresholds [11] . Considering the improvements in assay methodology together with the recent clinical evidence supporting a lower target for testosterone suppression of <20 ng/dL, regulatory authorities might consider requesting evidence of efficacy in meeting this lower threshold to be included in product labels of currently approved products or for new products. This would ensure that patients and healthcare professionals have more information for optimal treatment and management of advanced prostate cancer.
In the present analysis of four studies of all available dosing formulations of ADSC-LA, >90% of patients with advanced prostate cancer achieved and maintained the more rigorous threshold of serum testosterone (≤20 ng/dL), including the formulation with the longest duration of action (6-month). The 6-month formulation provides the longest duration of LA drug release available and presumably would be the most difficult to achieve efficacy over the entire dosing period. In the trial evaluating the efficacy of the 6-month ADSC-LA formulation, 92-96% of patients achieved and maintained serum testosterone of ≤20 ng/dL between weeks 6 and 24 of treatment. While mean testosterone concentrations across the four studies were <20 ng/dL at each end-of-study time point, mean testosterone concentrations were slightly higher for the 4-and 6-month formulations, compared with the shorter duration formulations. Although these increases may be due to study design factors, one can also speculate that the small difference in testosterone concentrations was a consequence of the extended drug release time.
To our knowledge, no other LHRH agonist has reported efficacy of testosterone suppression to ≤20 ng/dL from pivotal trials across the full range of doses. Limited studies have been published reporting any data on other available LHRH agonists achieving the lower threshold of serum testosterone with ADT. In one randomised study that included 89 patients with prostate cancer (36% advanced) treated with an i.m. administration and different formulation of LA lasting 1 month (7.5 mg dose), a post hoc analysis showed that 66% of patients reached the castration target of ≤20 ng/dL by 29 days after treatment [16] . In another randomised study that included 40 patients with advanced prostate cancer treated with 3.75 goserelin (20 patients) or 7.5 mg leuprolide (20) once monthly, 32% and 70%, respectively, achieved a target of ≤20 ng/dL by 3 months [17] . In a single-arm, phase III open-label study of 160 patients with prostate cancer (25% advanced) treated with a 1-month LA 3.75 mg i.m. depot, 73% achieved a testosterone concentration of ≤20 ng/dL by day 28 and 93% by day 168 [18] . Finally, several published case series have reported proportions of patients achieving testosterone concentrations of ≤20 ng/dL. In these case series, between 49% and 92% of patients achieved the lower threshold [9, [19] [20] [21] . A review of the published literature reveals two key uncertainties about attainment of the lower threshold value. First, only a few studies, in particular from prospective study cohorts, have investigated whether more rigorous serum testosterone targets are achieved with various formulations of leuprolide. Second, in the studies published to date, there is considerable inconsistency regarding testosterone suppression levels to ≤20 ng/dL for the approved class of LHRH agonist drugs.
There are several limitations of the present analysis. First, the studies were of moderate size and had moderate follow-up durations. Furthermore, there were no mortality or disease progression endpoints captured. The strengths of the present analysis included the breadth of data from four independent prospective study cohorts; consistent, well-defined, and representative patient populations; and similar data collection endpoints and techniques.
In conclusion, the safety and efficacy of a range of ADSC-LA dose formulations have been evaluated for treatment of advanced adenocarcinoma of the prostate, and ADSC-LA has been USA Food and Drug Administration (FDA) approved in four formulations. For each of the four trials and dosing formulations analysed, ADSC-LA rapidly achieved and maintained consistent mean serum testosterone concentrations below the more rigorous definition of castration, with mean (SE) testosterone concentrations of 6.1 (0.4), 10.1 (0.7), 12.4 (0.8), 12.6 (2.1) for the 1-, 3-, 4-, and 6-month formulations, respectively, at the end of each study, and >90% of patients achieved and maintained testosterone suppression below 20 ng/dL over the full dose period. This consistent suppression of testosterone in view of the current understanding of castrate-resistant prostate cancer is clearly desirable and may represent an important metric for improving cancer-specific survival, and delaying biochemical recurrence and clinical progression in prostate cancer.
